Novogen Limited , today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. The latest study looked at the ability of TRXE-009 to kill a library of patient-derived cell cultures from subjects with glioblastoma multiform .
http://ift.tt/1DMLX1n
http://ift.tt/1DMLX1n
No comments:
Post a Comment